Martin Gouldstone
Chief Executive Officer
Martin brings 30 years corporate finance and business development experience in the CRO, healthcare and pharmaceutical sectors to his role as CEO at Onciumme. Most recently, Martin was a Global SVP Business Development at Owkin, where he managed all of the commercial teams in the USA and Europe and led new strategic research partnerships. Over the last few years, Martin was Chief Business Officer at Sensyne Health where he helped to drive growth with particular focus on expanding reach in the US market and Pharmaceutical sector; Global SVP at Syneos One and Head of Capital Solutions for Syneos Healthcare where he developed and led Capital Solutions service; Chief Business Officer at BenevolentAI where he was responsible for all commercial activities. He was previously a Partner at Results Healthcare, where he co-led the healthcare practice;Head of Lifesciences in the UK for BDO, the Lead for the M&A process in Europe for Quintiles, and Business Development and Licensing Lead at Confirmant, Pharmacopeia, Sareum. He has extensive experience buying and selling multi-billion dollar deals across Europe and the US, architecting end to end portfolio out-sourcing deals, and negotiating multi-year research partnerships. Currently, Martin is a Non-Executive Board Director for Open Orphan Plc and sits on the Board of Trustees of Orthopaedic Research UK. He holds a BSc in Genetics and has completed a range of post graduate management courses.
Ron Kirschner
Chief Operating Officer
Ron joined Oncimmune in April 2020, as part of its Senior Leadership Team and supporting its Board of Directors. Ron has previously held executive and leadership positions in several life science companies.
Ron is a qualified lawyer with over 18 years of experience in advising international companies, including those in the bio-technology and healthcare sector. Ron began his career in the corporate team of Allen & Overy, in its London, Hong Kong and Bangkok offices, before moving to Baker & McKenzie, the international law firm. Ron has also held senior in-house positions, including in Barclays Bank and Genus Plc, where he was interim General Counsel and Smith & Nephew plc, the London-listed global medical devices company, where he led the legal team supporting the European commercial operations and was a member of Smith & Nephew’s UK management team.
Ron has extensive international experience, having spent several years working in Asia and regularly advising on international transactions.
Ron graduated from the University of Birmingham with an LLB in Law & Business Studies. He is admitted to practice law in England and Wales.
Martin Hudson
Finance Director
Martin graduated from the University of Liverpool with a Bachelor of Science degree in Mathematical Sciences with German, and has since worked for more than 20 years in commercially and operationally focused finance roles. He brings international experience in fast-moving project-driven high technology sectors.
Martin became a member of the Chartered Institute of Management Accountants while working at Ford of Europe in the UK and Germany. He moved to an EMEA FP&A role at Gilbarco Veeder Root, a subsidiary of Danaher, and then to McLaren Automotive where he was responsible for the financial control of vehicle development programmes and operational set up at a time of significant investment. Between 2012 and 2021, Martin held Finance Director roles at McLaren Electronic Systems, McLaren Applied Technologies and Williams Advanced Engineering, contributing to the growth of all three companies in their core areas of automotive and motorsport, as well as in adjacent markets including healthcare and financial services. Before joining Oncimmune in 2023, Martin was Director of Project Finance at a Slovakian battery company incorporated in Norway.